CSCIF (Cosciens Biopharma) GF Value Rank: 9 (As of Jul. 03, 2026) — 350% Above Median


CSCIF Cosciens Biopharma Inc CSCIF
61 GF Score
Price $7.35
GF Value $2.80
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Cosciens Biopharma GF Value Rank?

Cosciens Biopharma CSCIF +6.52% 61 GF Value Rank is 9 as of Jul. 03, 2026, which is 350% above its 10-year median of 2.00. GuruFocus rates CSCIF with a GF Score™ of 61/100 and a GF Value™ of $2.80 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Cosciens Biopharma has the GF Value Rank of 9.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Cosciens Biopharma GF Value Rank Related Terms

CSCIF vs VRTX, REGN, ALNY: GF Value Rank Comparison

For the Biotechnology subindustry, Cosciens Biopharma's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cosciens Biopharma GF Value Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's GF Value Rank falls into.


CSCIF
61GF Score
Cosciens Biopharma Inc CSCIF
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 9 mean?
Cosciens Biopharma (CSCIF) has a GF Value Rank of 9 as of Jul. 03, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Cosciens Biopharma and its competitors. This is 350% above median its historical median of 2.00. Over the past decade, Cosciens Biopharma's GF Value Rank has ranged from 2.00 to 10.00.
Is Cosciens Biopharma's GF Value Rank too high?
Cosciens Biopharma's current GF Value Rank of 9 is 350% above median its 10-year median of 2.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's GF Value Rank compare to VRTX and REGN?
Cosciens Biopharma's GF Value Rank of 9 can be compared against companies in the Biotechnology industry. Historically, Cosciens Biopharma's own GF Value Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Biotechnology company?
A good GF Value Rank depends on the Biotechnology industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current GF Value Rank is 9, which is 350% above median its own 10-year median of 2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.80, compared to a current price of $7.35 — trading 162.5% above its estimated fair value. The current GF Value Rank is 9, which is 350% above median its 10-year median of 2.00. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current GF Value Rank is 9 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be overvalued. The current stock price of $7.35 is trading 162.5% above its estimated GF Value™ of $2.80. GuruFocus considers Cosciens Biopharma to be Significantly Overvalued.

Key valuation signals for CSCIF:

  • GF Value Rank: 9 (350% above median its 10-year median of 2.00)
  • GF Value™: $2.80 vs. price of $7.35 (162.5% above fair value)
  • GF Score™: 61/100 with 6 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score

Get the complete analysis for CSCIF

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.35
Price
$2.80
GF Value